Bloomberg Intelligence’s Sam Fazeli discusses AbbVie’s $10.9 billion acquisition of Apogee Therapeutics. The deal enhances AbbVie’s presence in dermatology by adding treatments for atopic dermatitis, commonly known as eczema, to its portfolio. He speaks on “Bloomberg Open Interest.” (Source: Bloomberg)
Trending
- Review: Neagley is a worthy spinoff to megahit Reacher
- 2027: I’m not sure Sowore is running for office — Donald Duke
- Enugu Air launches direct Enugu-Douala flights
- Ruling house leaders seek N1bn damages, injunction against 12 family members
- iPhone owners can now submit a claim in Apple’s $250 million Siri AI lawsuit
- What’s the US–China AI ‘hotline’ that Trump plans to pitch to Xi Jinping? | Technology News
- Lagos govt disputes claim Alimosho hospital has only one dialysis machine
- ‘Jaw-dropping’: Super El Niño bursts through temperature record months ahead of peak | El Niño southern oscillation
